Epigenomes as therapeutic targets

Alberts, 2002, Molecular biology of the cell Alland, 1997, Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression, Nature, 387, 49, 10.1038/387049a0 Annunziato, 2008, DNA packaging: Nucleosomes and chromatin Asgatay, 2014, Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1, J Med Chem, 57, 421, 10.1021/jm401419p Azad, 2013, The future of epigenetic therapy in solid tumours—Lessons from the past, Nat Rev Clin Oncol, 10, 256, 10.1038/nrclinonc.2013.42 Balch, 2013, Epigenetic targeting therapies to overcome chemotherapy resistance, Adv Exp Med Biol, 754, 285, 10.1007/978-1-4419-9967-2_14 Bauman, 2012, A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies, Cancer Chemother Pharmacol, 69, 547, 10.1007/s00280-011-1729-2 Bergman, 2013, DNA methylation dynamics in health and disease, Nat Struct Mol Biol, 20, 274, 10.1038/nsmb.2518 Beumer, 2006, Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice, Clin Cancer Res, 12, 7483, 10.1158/1078-0432.CCR-06-1250 Beumer, 2008, Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU), Cancer Chemother Pharmacol, 62, 363, 10.1007/s00280-007-0603-8 Bionor_Pharma Bird, 2002, DNA methylation patterns and epigenetic memory, Genes Dev, 16, 6, 10.1101/gad.947102 Borthakur, 2008, Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine, Leuk Lymphoma, 49, 690, 10.1080/10428190701882146 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Brownell, 1996, Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation, Cell, 84, 843, 10.1016/S0092-8674(00)81063-6 Cantone, 2013, Epigenetic programming and reprogramming during development, Nat Struct Mol Biol, 20, 282, 10.1038/nsmb.2489 Chang, 2012, The role of EZH2 in tumour progression, Br J Cancer, 106, 243, 10.1038/bjc.2011.551 Chatagnon, 2011, Preferential binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions, Epigenetics, 6, 1295, 10.4161/epi.6.11.17875 Cheng, 2010, Coordinated chromatin control: Structural and functional linkage of DNA and histone methylation, Biochemistry, 49, 2999, 10.1021/bi100213t Chia, 2012, TET inhibitors as potential new cancer drugs — An enzyme that converts 5-methylcytosine to 5-hydroxymethylcytosine, Int Drug Discov←, Vol. 2014 Cocozza, 2011, CpG islands undermethylation in human genomic regions under selective pressure, PLoS ONE, 6, e23156, 10.1371/journal.pone.0023156 Coppede, 2014, The potential of epigenetic therapies in neurodegenerative diseases, Front Genet, 5, 220 Coppieters, 2013, Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain, Neurobiol Aging, 1334, 10.1016/j.neurobiolaging.2013.11.031 Coral, 2013, Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide, Cancer Immunol Immunother, 62, 605, 10.1007/s00262-012-1365-7 Costa, 2008, Non-coding RNAs, epigenetics and complexity, Gene, 410, 9, 10.1016/j.gene.2007.12.008 Costa, 2010, Epigenomics in cancer management, Cancer Manag Res, 2, 255, 10.2147/CMAR.S7280 Costa, 2007, Concise review: Cancer/testis antigens, stem cells, and cancer, Stem Cells, 25, 707, 10.1634/stemcells.2006-0469 Crea, 2012, EZH2 inhibition: Targeting the crossroad of tumor invasion and angiogenesis, Cancer Metastasis Rev, 31, 753, 10.1007/s10555-012-9387-3 Delatte, 2013, TET proteins: On the frenetic hunt for new cytosine modifications, Brief Funct Genomics, 12, 191, 10.1093/bfgp/elt010 Dodge, 2005, Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization, J Biol Chem, 280, 17986, 10.1074/jbc.M413246200 Dokmanovic, 2007, Histone deacetylase inhibitors: Overview and perspectives, Mol Cancer Res, 5, 981, 10.1158/1541-7786.MCR-07-0324 Eden, 2003, Chromosomal instability and tumors promoted by DNA hypomethylation, Science, 300, 455, 10.1126/science.1083557 Feinberg, 2007, Phenotypic plasticity and the epigenetics of human disease, Nature, 447, 433, 10.1038/nature05919 Feinberg, 2004, The history of cancer epigenetics, Nat Rev Cancer, 4, 143, 10.1038/nrc1279 Fernandez, 2012, De novo DNA methyltransferases: Oncogenes, tumor suppressors, or both?, Trends Genet, 28, 474, 10.1016/j.tig.2012.05.006 Fisher, 2011, Chromatin states in pluripotent, differentiated, and reprogrammed cells, Curr Opin Genet Dev, 21, 140, 10.1016/j.gde.2011.01.015 Flatau, 1984, DNA methylation in 5-aza-2′-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells, Mol Cell Biol, 4, 2098, 10.1128/MCB.4.10.2098 Gaudet, 2003, Induction of tumors in mice by genomic hypomethylation, Science, 300, 489, 10.1126/science.1083558 Glozak, 2005, Acetylation and deacetylation of non-histone proteins, Gene, 363, 15, 10.1016/j.gene.2005.09.010 Greger, 1989, Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma, Hum Genet, 83, 155, 10.1007/BF00286709 Groselj, 2013, Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair, Br J Cancer, 108, 748, 10.1038/bjc.2013.21 Hackett, 2013, Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine, Science, 339, 448, 10.1126/science.1229277 Hamm, 2011, The impact of epigenomics on future drug design and new therapies, Drug Discov Today, 16, 626, 10.1016/j.drudis.2011.04.007 Hassan, 2002, Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes, Cell, 111, 369, 10.1016/S0092-8674(02)01005-X He, 2011, Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA, Science, 333, 1303, 10.1126/science.1210944 Hebbes, 1988, A direct link between core histone acetylation and transcriptionally active chromatin, EMBO J, 7, 1395, 10.1002/j.1460-2075.1988.tb02956.x Hollenbach, 2010, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines, PLoS ONE, 5, e9001, 10.1371/journal.pone.0009001 Illingworth, 2010, Orphan CpG islands identify numerous conserved promoters in the mammalian genome, PLoS Genet, 6, e1001134, 10.1371/journal.pgen.1001134 Isobe, 2013, Activation-induced cytidine deaminase auto-activates and triggers aberrant gene expression, FEBS Lett, 587, 2487, 10.1016/j.febslet.2013.06.028 Issa, 2013, Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed/refractory acute myeloid leukemia Issa, 2013, First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML), Am Soc Hematol Issa, 2009, Targeting DNA methylation, Clin Cancer Res, 15, 3938, 10.1158/1078-0432.CCR-08-2783 Ito, 2010, Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification, Nature, 466, 1129, 10.1038/nature09303 Iurlaro, 2013, A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation, Genome Biol, 14, R119, 10.1186/gb-2013-14-10-r119 Jawert, 2013, Loss of 5-hydroxymethylcytosine and TET2 in oral squamous cell carcinoma, Anticancer Res, 33, 4325 Jayaraman, 2014, Novel methods of type 1 diabetes treatment, Discov Med, 17, 347 Jeong, 2014, Large conserved domains of low DNA methylation maintained by Dnmt3a, Nat Genet, 46, 17, 10.1038/ng.2836 Jones, 2012, Functions of DNA methylation: Islands, start sites, gene bodies and beyond, Nat Rev Genet, 13, 484, 10.1038/nrg3230 Jones, 2013 Jones, 2002, The fundamental role of epigenetic events in cancer, Nat Rev Genet, 3, 415, 10.1038/nrg816 Jurkin, 2011, Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis, Cell Cycle, 10, 406, 10.4161/cc.10.3.14712 Jurkowska, 2011, Structure and function of mammalian DNA methyltransferases, Chembiochem, 12, 206, 10.1002/cbic.201000195 Kaiser, 2013, Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma, Blood, 122, 219, 10.1182/blood-2013-03-487884 Kaminskas, 2005, FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension, Oncologist, 10, 176, 10.1634/theoncologist.10-3-176 Kantarjian, 2012, Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, J Clin Oncol, 30, 2670, 10.1200/JCO.2011.38.9429 Kantarjian, H. M. E. E. (2013). Drug Approvals in Acute Myeloid Leukemia: Can We Do Better?. The ASCO Post, 4. Karpf, 2006, A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy, Epigenetics, 1, 116, 10.4161/epi.1.3.2988 Kelly, 2013, The physiological roles of histone deacetylase (HDAC) 1 and 2: Complex co-stars with multiple leading parts, Biochem Soc Trans, 41, 741, 10.1042/BST20130010 Khan, 2010, Role of histone acetylation in cell physiology and diseases: An update, Clin Chim Acta, 411, 1401, 10.1016/j.cca.2010.06.020 Laille, 2014, Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies, J Clin Pharmacol, 54, 630, 10.1002/jcph.251 Laurent, 2010, Dynamic changes in the human methylome during differentiation, Genome Res, 20, 320, 10.1101/gr.101907.109 Li, 1992, Targeted mutation of the DNA methyltransferase gene results in embryonic lethality, Cell, 69, 915, 10.1016/0092-8674(92)90611-F Li, 1970, Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia, Cancer Res, 30, 2760 Lian, 2012, Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma, Cell, 150, 1135, 10.1016/j.cell.2012.07.033 Lister, 2009, Human DNA methylomes at base resolution show widespread epigenomic differences, Nature, 462, 315, 10.1038/nature08514 Liu, 2013, Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1, PLoS ONE, 8, e62828, 10.1371/journal.pone.0062828 Matei, 2012, Epigenetic resensitization to platinum in ovarian cancer, Cancer Res, 72, 2197, 10.1158/0008-5472.CAN-11-3909 Mellen, 2012, MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system, Cell, 151, 1417, 10.1016/j.cell.2012.11.022 Metzeler, 2012, DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia, Leukemia, 26, 1106, 10.1038/leu.2011.342 Miranda, 2007, DNA methylation: The nuts and bolts of repression, J Cell Physiol, 213, 384, 10.1002/jcp.21224 Mizzen, 1996, The TAF(II)250 subunit of TFIID has histone acetyltransferase activity, Cell, 87, 1261, 10.1016/S0092-8674(00)81821-8 Munoz, 2013, Activation-induced cytidine deaminase (AID) is necessary for the epithelial–mesenchymal transition in mammary epithelial cells, Proc Natl Acad Sci U S A, 110, E2977, 10.1073/pnas.1301021110 Munzel, 2011, 5-hydroxymethylcytosine, the sixth base of the genome, Angew Chem Int Ed Engl, 50, 6460, 10.1002/anie.201101547 Muramatsu, 2000, Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme, Cell, 102, 553, 10.1016/S0092-8674(00)00078-7 Odunsi, 2014, Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer, Cancer Immunol Res, 2, 37, 10.1158/2326-6066.CIR-13-0126 Okano, 1999, DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development, Cell, 99, 247, 10.1016/S0092-8674(00)81656-6 Okano, 1998, Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases, Nat Genet, 19, 219, 10.1038/890 Okazaki, 2007, Role of AID in tumorigenesis, Adv Immunol, 94, 245, 10.1016/S0065-2776(06)94008-5 Orr, 2012, Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma, PLoS ONE, 7, e41036, 10.1371/journal.pone.0041036 Pertea, 2010, Between a chicken and a grape: Estimating the number of human genes, Genome Biol, 11, 206, 10.1186/gb-2010-11-5-206 Peters, 2013, Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas, Mol Cell Biol, 33, 4321, 10.1128/MCB.00776-13 Piccolo, 2014, Getting rid of DNA methylation, Trends Cell Biol, 24, 136, 10.1016/j.tcb.2013.09.001 Pogribny, 2009, DNA hypomethylation in the origin and pathogenesis of human diseases, Cell Mol Life Sci, 66, 2249, 10.1007/s00018-009-0015-5 Portela, 2010, Epigenetic modifications and human disease, Nat Biotechnol, 28, 1057, 10.1038/nbt.1685 Pradhan, 1999, Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation, J Biol Chem, 274, 33002, 10.1074/jbc.274.46.33002 Qin, 2009, Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines, Blood, 113, 659, 10.1182/blood-2008-02-140038 Ramsahoye, 2000, Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a, Proc Natl Acad Sci U S A, 97, 5237, 10.1073/pnas.97.10.5237 Ray-Gallet, 2010, Nucleosome dynamics and histone variants, Essays Biochem, 48, 75, 10.1042/bse0480075 Reik, 2001, Epigenetic reprogramming in mammalian development, Science, 293, 1089, 10.1126/science.1063443 Reither, 2003, Catalytic mechanism of DNA-(cytosine-C5)-methyltransferases revisited: covalent intermediate formation is not essential for methyl group transfer by the murine Dnmt3a enzyme, J Mol Biol, 329, 675, 10.1016/S0022-2836(03)00509-6 Ren, 2011, DNA hypermethylation as a chemotherapy target, Cell Signal, 23, 1082, 10.1016/j.cellsig.2011.02.003 Rishi, 2010, CpG methylation of half-CRE sequences creates C/EBP alpha binding sites that activate some tissue-specific genes, Proc Natl Acad Sci U S A, 107, 20311, 10.1073/pnas.1008688107 Robertson, 1999, The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors, Nucleic Acids Res, 27, 2291, 10.1093/nar/27.11.2291 Robinson, 2013, An HDAC in the cytoplasm, not the nucleus, plays a pathogenic role in Huntington's disease, PLoS Biol, 11, e1001718, 10.1371/journal.pbio.1001718 Royce, 2014, Histone deacetylases and their inhibitors: New implications for asthma and chronic respiratory conditions, Curr Opin Allergy Clin Immunol, 14, 44, 10.1097/ACI.0000000000000029 Sanchez, 2009, The role of human bromodomains in chromatin biology and gene transcription, Curr Opin Drug Discov Devel, 12, 659 Sandoval, 2012, Cancer epigenomics: Beyond genomics, Curr Opin Genet Dev, 22, 50, 10.1016/j.gde.2012.02.008 Santos, 2002, Dynamic reprogramming of DNA methylation in the early mouse embryo, Dev Biol, 241, 172, 10.1006/dbio.2001.0501 Schaefer, 2010, Solving the Dnmt2 enigma, Chromosoma, 119, 35, 10.1007/s00412-009-0240-6 Stresemann, 2008, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, Int J Cancer, 123, 8, 10.1002/ijc.23607 Struhl, 1998, Histone acetylation and transcriptional regulatory mechanisms, Genes Dev, 12, 599, 10.1101/gad.12.5.599 Tahiliani, 2009, Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1, Science, 324, 930, 10.1126/science.1170116 Tao, 2014, Histone deacetylases in cardiac fibrosis: Current perspectives for therapy, Cell Signal, 26, 521, 10.1016/j.cellsig.2013.11.037 Tellez, 2014, SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome, Int J Cancer, 135, 2223, 10.1002/ijc.28865 Temiz, 2012, The role of methylation in the intrinsic dynamics of B- and Z-DNA, PLoS ONE, 7, e35558, 10.1371/journal.pone.0035558 Waddington, 1939 Wei, 2014, Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing, PLoS Pathog, 10, e1004071, 10.1371/journal.ppat.1004071 Wolffe, 1999, Epigenetics: Regulation through repression, Science, 286, 481, 10.1126/science.286.5439.481 Woodcock, 2010, Chromatin higher-order structure and dynamics, Cold Spring Harb Perspect Biol, 2, a000596, 10.1101/cshperspect.a000596 Wrangle, 2013, Alterations of immune response of non-small cell lung cancer with azacytidine, Oncotarget, 4, 2067, 10.18632/oncotarget.1542 Wright, 2013, Epigenetics: Reversible tags, Nature, 498, S10, 10.1038/498S10a Wu, 2011, Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells, Nature, 473, 389, 10.1038/nature09934 Yan, 2011, Evidence for non-CpG methylation in mammals, Exp Cell Res, 317, 2555, 10.1016/j.yexcr.2011.08.019 Yang, 2013, Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation, Oncogene, 32, 663, 10.1038/onc.2012.67 Yang, 2010, Targeting DNA methylation for epigenetic therapy, Trends Pharmacol Sci, 31, 536, 10.1016/j.tips.2010.08.001 Yang, 2007, HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention, Oncogene, 26, 5310, 10.1038/sj.onc.1210599 Yao, 2011, Beyond histone and deacetylase: An overview of cytoplasmic histone deacetylases and their nonhistone substrates, J Biomed Biotechnol, 2011, 146493, 10.1155/2011/146493 Ye, 2013, 5-hydroxymethylcytosine: A new insight into epigenetics in cancer, Cancer Biol Ther, 15 Yoo, 2007, Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides, Cancer Res, 67, 6400, 10.1158/0008-5472.CAN-07-0251 Yoo, 2006, Epigenetic therapy of cancer: Past, present and future, Nat Rev Drug Discov, 5, 37, 10.1038/nrd1930 Yoo, 2013, Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: Implications for the mechanism of inhibition of DNMTs, PLoS ONE, 8, e62152, 10.1371/journal.pone.0062152 Zhao, 2012, Inhibition of cancer cell proliferation by 5-fluoro-2′-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway, Springerplus, 1, 65, 10.1186/2193-1801-1-65